25 March 2024
Futura Medical
plc
("Futura" or the
"Company")
Notice of Results and
Investor Presentation
Futura Medical plc (AIM:
FUM), the consumer healthcare company
behind Eroxon, that specialises in the development
and global commercialisation of innovative and clinically
proven sexual health products, will announce its results for
the year ended 31 December 2023 on Wednesday 10 April
2024.
James Barder, Chief Executive
Officer and Angela Hildreth, Finance Director will provide a live
presentation for investors via the Investor Meet Company platform
on 10 April 2024, at 09:00 BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via the Investor Meet Company dashboard up until 09:00
BST the day before, or at any time during the live
presentation.
Investors can register for the
presentation via the following link:
https://www.investormeetcompany.com/futura-medical-plc/register-investor
Investors who already follow Futura
Medical plc on the Investor Meet Company platform will
automatically be invited.
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Liberum
Nominated Adviser
and Broker
|
Phil Walker
Ben Cryer
Nikhil Varghese
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.